

CURRICULUM VITAE

NAME: Botticelli Andrea

TITLE: Medical Doctor, assistant professor

HOSPITAL ADDRESS: Sant' Andrea Hospital - Via di Grottarossa, 1035-1039- ROME-ITALY

EDUCATION

2009 Graduation in Medicine - "Sapienza" University of Rome

2010 Medical license acquired . "Sapienza" University of Rome

2010 Medical Register in Rome; position: 57700

PROFESSIONAL CAREER

2005-2006 Internship - Division of Molecular Oncology Prof. Gulino La Sapienza University of Rome

2006-2009 Internship - Division of Medical Oncology - Sant'Andrea Hospital, Rome. Director: Prof. P. Marchetti

Since 2010 School of Specialization in Medical Oncology- "Sapienza" University- 2nd Faculty of Medicine- Sant'Andrea Hospital, Rome

20.05.2015 Specialization in Medical Oncology "Sapienza" University of Rome
"Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort." Prof. Paolo Marchetti

since November 2015 PhD "Sapienza" University of Rome.
: "Measurement of Circulating free DNA in advanced breast cancer patients treated with Exemestane + Everolimus."

since 2016 **COORDINATOR AND TEACHER** IMMUNO-ONCOLOGY MASTER II LEVEL, Sapienza , University of Rome

since May 2018 Assistant Professor (RTDA) , Clinical and Molecular Department , Sapienza University of Rome

WINNER : PREMIO ATENEIO, SAPIENZA UNIVERSITY OF Rome : avvio alla ricerca 2016-2017

Winner Preceptorship ESMO, Immuno-Oncology Congresso 29 September -1 October 2016

MOST RECENT PUBLICATIONS

Mazzuca F, Botticelli A, Marchetti P.

Paziente anziana con malattia della mammella metastatica in terapia ormonale con inibitore dell'aromatasi. Case report.

Recenti Progressi in Oncologia 2010.

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.

Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850.

La Torre M, Mazzuca F, Ferri M, Mari FS, Botticelli A, Pillozzi E, Lorenzon L, Osti MF, Marchetti P, Maurizi Enrico R, Ziparo V. The importance of lymph node retrieval and lymph node ratio following preoperative chemoradiation of rectal cancer. Colorectal Dis. 2013 Apr 13.

Botticelli A, De Francesco GP, Di Stefano D. Breast metastasis from clear cell renal cell carcinoma. J Ultrasound. 2013 Jul 5;16(3):127-30.

La Torre M, Nigri G, Mazzuca F, Ferri M, Botticelli A, Lorenzon L, Pillozzi E, Ziparo V. Standard versus limited colon resection for high risk T1 colon cancer. A matched case-control study. J Gastrointest Liver Dis. 2014 Sep;23(3):285-90.

Federica Mazzuca, Andrea Botticelli, Paolo Marchetti Impiego dei G-CSF in profilassi nella pratica clinica MYOSOTIS Anno 2, N. 4, dicembre 2014, 9-12

A Botticelli, F Mazzuca, C Maddalena, P Marchetti Everolimus and lung atypical carcinoid: case report Lung Cancer Management 3 (6), 435-438

Mercantini P, Lorenzon L, Mazzuca F, Botticelli A, Tarantino G, Balducci G, Marchetti P, Ferri M. Electro-chemotherapy treatment of cutaneous metastases from breast cancer. The American surgeon 05/2015; 81(5):e222-e225

Botticelli Andrea, Mazzotti Eva, Di Stefano Domenica, Petrocelli Viviana, Mazzuca

Federica, La Torre Marco ,Ciabatta Francesca Romana , Giovagnoli Maria Rosaria, Marchetti Paolo, Bonifacino Adriana. Positive impact of Elastography in breast cancer diagnosis: an institutional experience. *Journal of ultrasound* 18 (4), 321-327 2015

Mazzuca Federica , Borro Marina, Botticelli Andrea, Aimati Laura , Gentile Giovanna , Capalbo Carlo , Maddalena Chiara, Mazzotti Eva , Simmaco Maurizio , Marchetti Paolo. Effect of MTHFR polymorphisms on gastrointestinal cancer risk in Italy. *World Journal of Oncology* 6 (4), 394-39 2015

A Botticelli, F Mazzuca, M Borro, E Mazzotti, M La Torre, Adriana Bonifacino, Francesca Romana Ciabatta, Giovanna Gentile, Chiara Maddalena, Maurizio Simmaco, Paolo Marchetti FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value? *World Journal of Oncology* 6 (5), 437- 440 2015

Giovanna Gentile, Andrea Botticelli, Luana Lionetto, Federica Mazzuca, Maurizio Simmaco, Paolo Marchetti, Marina Borro Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate *DPYD* haplotype to improve toxicity prediction. *Pharmacogenomics J.* 2015 Jul 28. doi: 10.1038/tpj.2015.56.

Mazzuca Federica, Botticelli Andrea, Mazzotti Eva, La Torre Marco, Borro Marina, Marchetti Luca , Maddalena Chiara, Gentile Giovanna , Ziparo Vincenzo, Simmaco Maurizio, Marchetti Paolo. CYP19A1 genetic polymorphisms rs4646 and osteoporosis in patients treated with aromatase inhibitor-based adjuvant therapy: a pilot study. *Eurasian J Med* 2016; 48:10-14)DOI: 10.5152/eurasianjmed.2016.008

Federica Mazzuca, Marina Borro, Botticelli Andrea, Eva Mazzotti, Marco La Torre, Luana Lionetto, Giovanna Gentile, Maurizio Simmaco, Paolo Marchetti. Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. DOI: 10.18632/oncotarget.7991.2016

Romiti A, Roberto M, D'Antonio C, Onesti CE, Barucca V, Milano A, Gentile G, Lionetto L, Medda E, Mazzuca F, Botticelli A, Falcone R, Simmaco M, Marchetti P. The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. *Anticancer Drugs.* 2016 Aug 23.

Andrea Botticelli, Marina Borro, Concetta Elisa Onesti, Lidia Strigari, Giovanna Gentile, Bruna Cerbelli, Adriana Romiti, Mario Occhipinti, Claudia Sebastiani, Luana Lionetto, Luca Marchetti, Maurizio Simmaco, Paolo Marchetti, Federica Mazzuca Degradation Rate of 5-fluorouracil in Metastatic Colorectal Cancer: a new predictive outcome biomarker? *PLoS One.* 2016 Sep 22;11(9):e0163105.doi:10.1371/journal.pone.0163105. eCollection 2016

Borro M, Botticelli A, Mazzuca F, Onesti EC, Gentile G, Romiti A, Cerbelli B, Mazzotti E, Marchetti L, Lionetto L, Simmaco M, Marchetti P. Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. *Oncotarget.* 2016 Oct 11. doi: 10.18632/oncotarget.12571. Corresponding author : Andrea Botticelli

Botticelli A., Zizzari I.G., Mazzuca F. ,Ascierto P. , Putignani L., Marchetti L., Napoletano C., Nuti M. Marchetti P. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.

Oncotarget. 2016 Oct 28. doi: 10.18632/oncotarget.12985. [Epub ahead of print]
Review

F.Mazzuca, A.Petremolo, M Piras , A. Botticelli. *Persistenza della risposta completa al trattamento con cetuximab in paziente affetto da adenocarcinoma del colon-retto metastatico: caso clinico.* EVIDENZE-CASI CLINICI IN ONCOLOGIA 2016.

Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. *Anticancer Drugs.* 2016 Nov 1

Roberto M, Romiti A, Botticelli A, Mazzuca F, Lionetto L, Gentile G, Paris I, Falcone R, Bassanelli M, Di Pietro FR, Onesti CE, Anselmi E, Macrini S, Simmaco M, Marchetti P. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. *Eur J Clin Pharmacol.* 2016 Nov 18

Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F.

A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. *Anticancer Drugs.* 2017 Mar 14. doi: 10.1097/CAD.0000000000000492.

Silvia Angelini, Andrea Botticelli, Concetta Elisa Onesti, Raffaele Giusti, Valentina Sini, Valeria Durante, Lidia Strigari, Giovanna Gentile, Bruna Cerbelli, Patrizia, Pellegrini, Valentina Sgroi, Alessandro Rossi, Mario Occhipinti, Francesca Romana Di Pietro, Maurizio Simmaco, Federica Mazzuca, Paolo Marchetti Pharmacogenetic approach to toxicity in breast cancer patients treated with taxanes. *ANTICANCER RESEARCH* 2017 May;37(5):2633-2639. PMID:28476838

Sini Valentina, Andrea Botticelli, Lunardi GianLuigi, Gori Stefania, Paolo Marchetti. Pharmacogenetics and aromatase inhibitor side effects in the treatment of breast cancer. *Pharmacogenomics.* 2017 Jun 8. doi: 10.2217/pgs-2017-0006.

Patrizia Vici, Laura Pizzuti, Andrea Michelotti, Isabella Sperduti, Clara Natoli, Lucia Mentuccia, Luigi Di Lauro, Domenico Sergi, Paolo Marchetti, Daniele Santini, Emanuela Magnolfi, Laura Iezzi, Luca Moscetti, Agnese Fabbri, Alessandra Cassano¹⁰, Antonino Grassadonia, Claudia Omarini, Federico Piacentini, Andrea Botticelli, Ilaria Bertolini, Angelo Fedele Scinto, Germano Zampa, Maria Mauri, Loretta D'Onofrio, Valentina Sini, Maddalena Barba, Marcello Maugeri-Saccà, Ernesto Rossi, Elisabetta Landucci, Silverio Tomao, Antonio Maria Alberti, Francesco Giotta, Corrado Ficorella, Vincenzo Adamo, Antonio Russo, Vito Lorusso, Katia Cannita, Sandro Barni, Lucio Laudadio, Filippo Greco, Ornella Garrone, Marina Della Giulia, Paolo Marolla, Giuseppe Sanguineti, Barbara Di Cocco, Gennaro Ciliberto, Ruggero De Maria and Teresa Gamucci. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. *ONCOTARGET* May 2017 DOI: 10.18632/oncotarget.18176

Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting. *P.J Cell Physiol.* 2017 Jul 15. doi: 10.1002/jcp.26103.

Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, Passalacqua R, Braconi C, Petrelli F. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. *HPB (Oxford)*. 2017 Jul 3. pii: S1365-182X(17)30804-3. doi: 10.1016/j.hpb.2017.05.010.

Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Filippo SD, Lauro LD, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. *Sci Rep*. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.

Mario Occhipinti, Rosa Falcone, Concetta Elisa Onesti, Andrea Botticelli, Federica Mazzuca, Paolo Marchetti, Salvatore Lauro Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. *Journal of Thoracic Disease* 3 (2) doi: 10.21037/jtd.2017.09.74

Andrea Botticelli, Concetta Elisa Onesti, Ilaria Zizzari, Bruna Cerbelli, Paolo Sciattella, Mario Occhipinti, Michela Roberto, Francesca Di Pietro, Adriana Bonifacino, Michele Ghidini, Patrizia Vici, Laura Pizzuti, Chiara Napoletano, Lidia Strigari, Giulia D'Amati, Federica Mazzuca, Marianna Nuti, Paolo Marchetti The sexist behaviour of immune checkpoint inhibitors in cancer therapy? *Oncotarget* November 2017 DOI 10.18632/oncotarget.22242

Bruna Cerbelli, Angelina Pernazza, Andrea Botticelli, Paolo Sciattella, Mariella Mauri, Lucio Fortunato, Massimo Monti, Domenico Campagna, Giuseppe Naso, Paolo Marchetti, Leopoldo Costarelli and Giulia D'Amati

"PD-L1 expression is in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy?" Accepted in press on *BioMed Research International*

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β -Catenin Pathway. *Cancer Immunol Res*. 2018 Apr 26. doi: 10.1158/2326-6066.CIR-17-0594

Milano A, Mazzetta F, Valente S, Ranieri D, Leone L, Botticelli A, Onesti CE, Lauro S, Raffa S, Torrisi MR, Marchetti P.

Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice.

Anal Cell Pathol (Amst). 2018 Feb 27;2018:3506874. doi: 10.1155/2018/3506874.

Salati M, Baldessari C, Cerbelli B, **Botticelli A**. Nivolumab in pretreated non-small cell lung cancer: continuing the immunolotion. *Transl Lung Cancer Res*. 2018 Apr;7(Suppl 2):S91-S94. doi: 10.21037/tlcr.2018.01.14. No abstract available. PMID:29782565

Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Mazzuca F, Onesti CE, Roberto M, Di Girolamo M, **Botticelli A**, Begini P, Strigari L, Marchetti P, Muscaritoli M. *Oncotarget*. 2018 May 22;9(39):25714-25722. doi: 10.18632/oncotarget.25394. eCollection 2018 May 22.

Nuti M, Zizzari I, Botticelli A., Putignani L., Marchetti P. The microbiota impact: Bacteria shaping immunity, disease and response to therapy June 2018 Translational Cancer Research 7(S5):S616-S619 DOI: 10.21037/tcr.2018.05.25

Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3.

Nuti M, Zizzari IG, Botticelli A, Rughetti A, Marchetti P. The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one. Cancer Treat Rev. 2018 Jul 26;70:41-46. doi: 10.1016/j.ctrv.2018.07.016.

ABSTRACT AND POSTER

Poster AIOM 2011, Supplementi di Tumori Volume 11 number 2 October 2011 SNPs and docetaxel response in advanced breast cancer De Iulius F., Russo I., Di Trapani M.C., Botticelli A., Gentile G, Simmaco M, Trasatto L. Roselli A., Pellegrini P., Marchetti P

Poster **attualità in senologia 2011** : **valutazione farmacogenomica della mieloe neurotossicità da taxani nelle pazienti affette da carcinoma mammario.** Francesca De Iulius, Maria Cristina Di Trapani, Ivana Russo, Andrea Botticelli, Arianna Roselli, Luciana Trasatti, Marzia Lo Russo, Valeria Vitale, Laura Bersigotti, Gianni Lazzarin, Patrizia Pellegrini, Paolo Marchetti

Poster SIOMMS 2012 **ADERENZA E TOLLERABILITÀ DELL'ACIDO ZOLEDRONICO IN PAZIENTI ANZIANE CON TUMORE DELLA MAMMELLA IN TERAPIA CON INIBITORI DELL'AROMATASI.** Devito, R. Benvenuto, P. Pellegrini, L. Trasatti, A. Botticelli, E. De Marinis, I. Indiano, L. Tafaro, P. Falaschi. UO Geriatria, Azienda Ospedaliera S. Andrea Facoltà di Medicina e Psicologia, Sapienza Università di Roma

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli ECPC-012 An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (Nab-Paclitaxel) Vs. Conventional Paclitaxel For Metastatic Breast Cancer Patients: The COSTANZA Study European Journal of Hospital Pharmacy: Science and Practice 20 (Suppl)20131 <http://dx.doi.org/10.1136/ejpharm-2013-000276.469>

Poster EBCC 2013 N 476 poster board 068 FcyR and FGFR4 polymorphisms associated with the pathological complete response (pCR) to trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. A. Botticelli, F. Mazzuca, M. La Torre, G. Gentile, P. Pellegrini, C. Maddalena, V. Sgroi, V. Ziparo, M. Simmaco, P. Marchetti

670PF. Mazzuca (Roma, Italy) A. Botticelli (Roma, Italy) L. Lionetto (Roma, Italy) M. La Torre (Roma, Italy) R. Giusti (Roma, Italy) C. Maddalena (Roma, Italy) P. Pellegrini (Roma, Italy) G. Gentile (Roma, Italy) F. Ciabatta (Roma, Italy) M. Borro (Roma, Italy) V. Ziparo (Roma, Italy) M. Simmaco (Roma, Italy) P. Marchetti (Roma, Italy) - Effect of degradation rate of 5-FU and genetic polymorphisms of DPD, TSER and MTHFR on toxicity and survival of 5-FU-based

chemotherapy in gastric cancer Ann Oncol (2014) 25 (suppl_4): iv228.DOI:<https://doi.org/10.1093/annonc/mdu334.55> Published:01 September 2014

AIOM2014 Effect of Degradation Rate of 5-FU and Genetic Polymorphisms of DPYD, TSER and MTHFR on Toxicity and Survival of 5-FU-based Chemotherapy in Metastatic Colorectal Cancer.
Botticelli A. , Mazzuca F., Maddalena C., La Torre M., Pellegrini P., Gentile G., Giusti R., Ciabatta F., Lionetto L., Borro M., Ziparo V., Simmaco M., Marchetti P.

AIOM2014 FcγR and FGFR4 polymorphisms related to Progression Free Survival in metastatic breast cancer patients treated with trastuzumab-based therapy Mazzuca F., Botticelli A. , Maddalena C., La Torre M., Pellegrini P., Gentile G., Ciabatta F. R., Lionetto L., Borro M., Ziparo V., Simmaco M., Marchetti P.

Effect of degradation rate of 5-FU and genetic polymorphisms of DPYD, TSER and MTHFR on toxicity of capecitabine in colorectal cancer.
Botticelli Andrea, Mazzuca Federica, Mazzotti Eva, Maddalena Chiara, Gentile Giovanna, Luana Lionetto, Marina Borro, Simmaco Maurizio, Marchetti Paolo.
European Journal of cancer 2015,51, SUPPL 3 DOI 10.1016/S0959-8049(16)31091-7

Botticelli Andrea, Mazzuca Federica, Mazzotti Eva, Di Girolamo Marco, Carbonetti Francesco, Casazza Ines, Luana Lionetto, Gentile Giovanna, Marina Borro, Simmaco Maurizio, Marchetti Paolo Sarcopenia and toxicities in patients affected by breast cancer in adjuvant treatment SABCS 2015

P-0395- Michela Roberto, Adriana Romiti, Luana Lionetto, Chiara D'Antonio, Concetta Onesti, Andrea Botticelli, Annalisa Milano, Rosa Falcone, Mario Occhipinti, Federica Mazzuca, Maurizio Simmaco, Paolo Marchetti Fluorouracil Degradation Rate in Patients with Recurrent Gastrointestinal Cancer Treated with Metronomic Capecitabine Article in Annals of Oncology 27(suppl 2) June 2016 DOI: 10.193/annonc/mdw199.37

M. Roberto A. Romiti A. Botticelli F.R. Di Pietro L. Lionetto G. Gentile F. Mazzuca R. Falcone M. Occhipinti S. Macrini E. Anselmi A. Petremolo C.E. Onesti M. Simmaco P. Marchetti 5-fluorouracil degradation rate as a predictive toxicity biomarker in early stage gastrointestinal cancer Ann Oncol (2016) 27 (suppl_6): 100P.DOI:<https://doi.org/10.1093/annonc/mdw363.48>

C.E. Onesti A. Botticelli F. Mazzuca S. Angelini A. Petremolo R. Falcone M. Roberto M. Occhipinti A. Romiti L. Lionetto M. Simmaco P. Marchetti 5-fluorouracil degradation rate (5-FU-DR) could predict toxicity in breast cancer patients treated with capecitabine Ann Oncol (2016) 27 (suppl_4): iv68. DOI:<https://doi.org/10.1093/annonc/mdw337.29> Published: 21 September 2016

C.E. Onesti A. Botticelli F. Mazzuca A. Milano A. Romiti M. Roberto R. Falcone M. Occhipinti F.R. Di Pietro L. Lionetto M. Simmaco P. Marchetti

5-fluorouracil degradation rate (5-FU-DR) as a new toxicity predictive biomarker for adjuvant FOLFOX in colorectal cancer (CRC) patients Ann Oncol (2016) 27 (suppl_6): 586P.DOI:<https://doi.org/10.1093/annonc/mdw370.134> Published:11 October 2016

M Occhipinti, A Botticelli, CE Onesti, M Ghidini, R Righini, C Pizzo, A Milano, G

Tomasello, FR Di Pietro, L Toppo, M Ratti, R Passalacqua, P Marchetti, F Mazzuca
Treatment and outcome for small bowel adenocarcinoma (SBA): a real life experience of two Italian centres
Annals of Oncology 28(suppl_6) October 2017
DOI 10.1093/annonc/mdx425.022

L Mentuccia, A Gelibter, I Sperduti, L D'onofrio, A Botticelli, P Vici, A Cassano, L Moschetti, L Carbognin, V Graziano, G Barchiesi, E Rossi, MC Cursano, L Pizzuti, I Paris, A Vaccaro, A Fabbri, L Rossi, R Samaritani, R Sarmiento, T Gamucci
Efficacy of pertuzumab in combination with trastuzumab and a taxane in first line treatment for metastatic breast cancer (MBC): a multicenter retrospective observational study
Annals of Oncology 35 (15_suppl), e12504-e12504 2017

A Botticelli, B Cerbelli, A Pernazza, CE Onesti, P Sciattella, L Costarelli, M Monti, D Campagna, F Mazzuca, L Fortunato, P Marchetti, G D'Amati
PPD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy?
Annals of Oncology September 2017 (Supl_5) DOI 10.1093/annonc/mdx363.027

Michele Ghidini, Andrea Botticelli, Bianca Maria Donida, Lidia Strigari, Concetta Elisa Onesti, Margherita Ratti, Claudio Pizzo, Federico Aldighieri, Laura Toppo, Valerio Ranieri, Mario Occhipinti, Chiara Senti, Giulia Tanzi, Federica Mazzuca, Paolo Marchetti, Mario Martinotti, Rodolfo Passalacqua, Gianluca Tomasello, Massimo Rovatti
Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers
Journal of Clinical Oncology 35 (15_suppl), e15588-e15588 2017

Laura Toppo, Wanda Liguigli, Chiara Senti, Gianluca Tomasello, Michele Ghidini, Margherita Ratti, Andrea Botticelli, Concetta Elisa Onesti, Francesca Di Pietro, Claudio Pizzo, Stefano Panni, Alessandra Curti, Rodolfo Passalacqua
Presence of bone metastases (BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC)
Journal of Clinical Oncology 35 (15_suppl), e15538-e15538 2017

Marianna Nuti, Ilaria Zizzari, Chiara Napoletano, Andrea Botticelli, Fabio Calabro, Alain Gelibter, Aurelia Rughetti, Alessio Ugolini, Ilary Ruscito, Federica Mazzuca, Hassan Rahimi, Concetta Elisa Onesti, Enrico Cortesi, Paolo Marchetti
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients.
Journal of Clinical Oncology 35 (15_suppl), e14506-e14506 2017

CE Onesti, A Botticelli, M Occhipinti, FR Di Pietro, I Zizzari, C Napoletano, M Nuti, S Lauro, F Mazzuca, P Marchetti
Early onset of endocrine alterations during PD-1 blockade in advanced NSCLC patients
Annals of Oncology 28 (suppl_2) 2017

Anatomic site of metastases can influence response to nivolumab in NSCLC patients.
A Botticelli, B Cerbelli, P Sciattella, M Salati, I Zizzari, M Roberto, G Poti, Federica De Galitiis, Vincenzo Picone, Giulia D'Amati, Federica Mazzuca, Marianna Nuti, Paolo Marchetti
Journal of Clinical Oncology 36 (15_suppl), e15021-e15021

Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage II-III colorectal or breast cancer: A blind, ...
F Mazzuca, M Roberto, A Botticelli, L Marchetti, E Sarfati, E Crimini, Francesca Schipilliti, Marco Di Girolamo, Maurizio Muscaritoli, Paolo Marchetti
Journal of Clinical Oncology 36 (15_suppl), TPS10129-TPS10129

Changes of microbiome profile during nivolumab treatment in NSCLC patients.
A Botticelli, L Putignani, I Zizzari, F Del Chierico, S Reddel, F Di Pietro, Andrea Quagliarello, Concetta Elisa Onesti, Giusti Raffaele, Federica Mazzuca, Marianna Nuti, Paolo Marchetti
Journal of Clinical Oncology 36 (15_suppl), e15020-e15020

The key role of kynurenine in antiPD-1 failure
A Botticelli, B Cerbelli, L Lionetto, I Zizzari, A Pisano, M Roberto, Michela Roberto, Concetta Elisa ONESTI, Francesca Di Pietro, Chiara Napoletano, Laura Pizzuti, Patrizia Vici, Giulia D'Amati, Federica Mazzuca, Maurizio Simmaco, Patrizia Nuti, Paolo Marchetti
AACR 2018

Rome, 29 october 2018